Crinetics Pharmaceuticals, Inc.
CRNX
$30.93
$0.842.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -43.05% | -39.41% | -39.10% | -39.36% | -40.59% |
| Total Depreciation and Amortization | 95.35% | 151.05% | 153.64% | 102.42% | 61.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 36.69% | 44.55% | 48.46% | 67.47% | 72.92% |
| Change in Net Operating Assets | -121.39% | -122.94% | 19.44% | 762.96% | 462.92% |
| Cash from Operations | -67.34% | -47.72% | -37.09% | -23.83% | -12.62% |
| Capital Expenditure | 10.77% | 37.52% | 18.00% | 6.88% | -456.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -72.21% | -170.67% | -191.72% | -61.01% | -361.61% |
| Cash from Investing | -70.54% | -165.65% | -186.82% | -57.42% | -369.59% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -19.32% | -20.43% | 157.62% | 37.64% | 5,457.95% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 8.67% | 23.06% | -111.57% | 22.35% | -11,861.04% |
| Cash from Financing | -19.83% | -20.29% | 160.31% | 41.36% | 5,320.35% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -194.60% | -184.95% | 843.34% | 55.94% | 1,296.94% |